Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on October 22, 2023. The filing discloses interim clinical data presented at the European Society for Medical Oncology Congress regarding two investigational androgen receptor (AR) degraders: bavdegalutamide (ARV-110) and ARV-766. The report also announces a strategic shift in the Company's clinical development priorities.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial updates and strategic changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial figures.
Material Changes and Clinical Data
Bavdegalutamide (ARV-110) Interim Data
- Population: Men with metastatic castration-resistant prostate cancer (mCRPC) post-novel hormonal agents (median 4 prior therapies).
- Efficacy in AR 878/875 Mutations: Median radiographic progression-free survival (rPFS) of 11.1 months (n=26) and PSA50 response rate of 54% in patients without co-occurring AR L702H mutations.
- Efficacy in Other AR LBD Mutations: Median rPFS of 8.2 months (n=45) and PSA50 response rate of 36% in patients with any AR LBD mutation except L702H alone.
- Limitation: Efficacy was greatly diminished in patients with AR L702H mutations, with a PSA50 rate of only 8%.
- Safety: Manageable tolerability with no Grade > 4 treatment-related adverse events (TRAEs). Most common TRAEs included nausea (56%) and fatigue (35%). Discontinuation rate due to TRAEs was 10%.
ARV-766 Interim Data
- Profile: Second-generation PROTAC designed to degrade all clinically relevant AR mutations, including L702H.
- Efficacy: PSA50 response rate of 41% in patients with any AR LBD mutation and 50% in patients with AR L702H mutations.
- Safety: Well-tolerated with no Grade > 4 TRAEs. Most common TRAEs included fatigue (29%) and nausea (14%). Discontinuation rate due to TRAEs was 4%.
Guidance, Outlook, and Strategic Shift
Based on superior tolerability and efficacy signals, Arvinas has decided to prioritize the initiation of a Phase 3 clinical trial with ARV-766 in mCRPC instead of the previously planned Phase 3 trial for bavdegalutamide. The Company plans to initiate discussions with regulatory authorities to align on the Phase 3 program by the second quarter of 2024. Ongoing trial activities for bavdegalutamide are expected to continue as planned, and the Company expects to advance ARV-766 to treat metastatic castration-sensitive prostate cancer (mCSPC) in the future.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the AR L702H mutation subgroups in the clinical data.
- Confirm the timeline for regulatory discussions regarding the ARV-766 Phase 3 program (targeted for 2Q 2024).
- Review the full text of the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2) for detailed statistical analysis.
- Assess the impact of the strategic pivot on the Company's cash burn rate and capital requirements, as this filing does not provide updated financial guidance.
- Monitor future filings for the official initiation of the ARV-766 Phase 3 trial.